Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations

This article was originally published in The Tan Sheet

Executive Summary

House Appropriations/agriculture subcommittee more than doubles FDA's budget for buildings and facilities from $8.4 mil. in FY 94 to just over $18 mil. in FY 95 at a May 26 budget markup. The increase is intended to cover the cost of replacing the agency's Los Angeles laboratory, which Chairman Richard Durbin (D-Ill.) called a "disaster" and a "dangerous place to work." The committee also provided FDA with $79 mil. in Rx user fees, consistent with funding levels authorized by the 1992 Prescription Drug User Fee Act, but only a fraction of the $343 mil. in user fees requested in the administration's FY 95 proposed budget. The subcommittee set the total level of FDA funding at $914 mil. plus user fees. In 1994, net government outlays were $873 mil. plus $61 mil. in user fee collections, for total funding of $934 mil

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel